Clinical trials: Advanced Malignant Solid Tumours
Malignant Neoplasm
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
- Trial name
- NCT07247110
- Testing
- MK-4716, Pembrolizumab, Cetuximab
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm
- Trial name
- NCT03213691
- Testing
- Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
This phase III trial compares olanzapine to placebo in decreasing nausea and vomiting in patients with cancer that has spread to other places in the body (advanced).
- Trial name
- NCT05403580
- Testing
- Olanzapine, Questionnaire Administration
- Sponsor
- Mayo Clinic
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
This phase Ib trial finds out the best dose, possible benefits and/or side effects of BAY1895344 and copanlisib in treating molecularly selected patients with solid tumors that have spread to other places in the body (advanced).
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT05010096
- Testing
- Copanlisib, Elimusertib
- Sponsor
- M.D. Anderson Cancer Center
B-cell Malignancies, Solid Tumors
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
This Phase I, open-label, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of SYS6005 in advanced malignancies, comprising dose-escalation and expansion phases.
- Trial name
- NCT06958679
- Testing
- SYS6005
- Where
- China
- Volunteers
- 132 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Solid Tumors
Kanitinib in Treating Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.
- Trial name
- NCT02916095
- Testing
- Kanitinib
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent
EpCAM CAR-T for Treatment of Advanced Solid Tumors
This study is for patients that have nasopharyngeal carcinoma, breast cancer, gastric cancer and other solid tumors. As epithelial cell adhesion molecule (EpCAM) is a well characterized molecule that is closely with poor…
- Conditions
- Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M), Breast Cancer Recurrent, Gastric Cancer With Metastasis
- Trial name
- NCT02915445
- Testing
- EpCAM CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Locally Advanced Malignant Neoplasm, Metastatic Cancer
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
The purpose of this study is to test the safety and efficacy of OMP-336B11. OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and…
- Trial name
- NCT03295942
- Testing
- OMP-336B11
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Neoplasms, Malignant
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Primary Objective: To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of related Dose Limiting…
- Trial name
- NCT01193595
- Testing
- Ombrabulin (AVE8062), bevacizumab
- Where
- 4 sites in France, Italy and 1 more
- Volunteers
- 39 people
- Sponsor
- Sanofi
Advanced Malignant Solid Tumor
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
- Trial name
- NCT06166472
- Testing
- AK132
- Where
- 7 sites in China
- Volunteers
- 72 people
- Sponsor
- Akeso
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
Advanced Malignant Solid Tumors
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase II clinical study. The primary objective is to evaluate the investigator-assessed objective response rate of JS212 and JS213 as monotherapy and in combination regimens in patients with…
- Trial name
- NCT07480733
- Testing
- JS212 for Injection, JS213 for Injection, JS207 for Injection
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Breast Cancer, Breast Neoplasm Malignant Female
PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer
This exploratory clinical study aims to assess the safety and preliminary efficacy of an immunotherapy using PD-1 knockout anti-MUC1 CAR-T cells in the treatment of advanced MUC1-positive breast cancer
- Trial name
- NCT05812326
- Testing
- AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Malignant Solid Tumour
Long-Term Compassionate Use Study for Continued Administration of SCB01A-01
The primary objective is to characterize the safety profile of long-term exposure to SCB01A when administered to cancer subjects with advanced solid tumors. Furthermore, the efficacy profile will also be explored in this study.
- Trial name
- NCT01151930
- Testing
- SCB01A
- Sponsor
- SynCore Biotechnology Co., Ltd.
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body…
- Trial name
- NCT04879121
- Testing
- Larotrectinib Sulfate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors
This study is an open-label, dose-escalation phase I clinical trial conducted in patients with advanced or metastatic solid tumors in China.This study is an open-label, dose-escalation phase I clinical trial conducted in patients…
- Trial name
- NCT07438093
- Testing
- Peginterferon α-2b plus an anti-PD-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Advanced Malignant Solid Tumor
Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Advanced Solid Tumors
This study aims to evaluate the safety and tolerability of lattice radiation therapy in combination with PD-1/PD-L1 inhibitors for patients with advanced solid tumors and large tumors, and to assess its efficacy.
- Trial name
- NCT07865793
- Testing
- lattice radiotherapy and PD-1/PD-L1 inhibitors
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439292
- Testing
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)